Hepatology

Refusal of hospital-administered birth doses of the hepatitis B vaccine declined in Washington, DC, from 2017-2022 despite pandemic-related disruptions to other childhood vaccines.

Findings underscore the importance of HCC screening adherence in patients with HCV-related cirrhosis who achieve HCV cure for improving overall survival.

Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.

Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

Shiffman reviews some of the key findings from AHFIRM, explaining important considerations for interpreting the results and potential reasons for regional differences in the data.

Shiffman describes the current treatment landscape for alcohol-associated hepatitis and what larsucosterol might offer for these patients.

The marketing authorization makes the Xpert HCV test and GeneXpert Xpress System the first point-of-care test for diagnosing HCV.

Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.

Ross-Driscoll explains how disparities in the liver transplant process begin prior to waitlisting and how findings from her research on referral and evaluation may inform interventions.

A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.

Gish explains recent developments in the treatment of PBC, highlighting the FDA approval of elafibranor, the anticipated decision for seladelpar, and the growing role of combination therapy.

In this video segment, Palak and Trivedi discuss strategies for improving the management of patients in real-world settings given recent advances in therapies and pathophysiology.

In this video segment, Palak and Trivedi dive into a discussion on emerging therapies and therapeutic targets for management of PBC.

In this video segment, Palak and Trivedi break down their perspectives on the current state of unmet need in primary biliary cholangitis from a clinical and patient perspective.

In this video segment, Palak and Trivedi discuss the approval of elafibranor and other therapies that could receive approval for management of primary biliary cholangitis in the near future.

In this video segment, Palak and Trivedi describe current and emerging diagnostic methods for primary biliary cholangitis.

Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.

Interim analyses of a pair of phase 2b studies highlight the IBAT inhibitor’s potential in adults with primary biliary cholangitis and primary sclerosing cholangitis.

The network meta-analysis found tenofovir disoproxil fumarate was more likely to achieve virologic response at week 48, while entecavir was superior for 48-week biochemical response.

Despite missing the primary endpoint among the global study population, additional analyses of participants from the US revealed significant impacts on mortality reduction with larsucosterol.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.